Some of the most prominent names in biotechnology plunged on Thursday as the Nasdaq headed for its worst day in nearly two years.
Read MoreThe latest on the markets
U.S. conglomerate Berkshire Hathaway has mandated banks for a potential debut euro-denominated bond deal.
Investors should not lose faith in the U.S. market, BMO Capital Markets' Brian Belski tells CNBC.
Investors need to be cautious on rotating into European equities, according to the CEO of an independent asset management group.
These tech names could be set to break out, and many of them are still below their 15-year-old, all-time highs.
Get the best of CNBC in your inbox